Scholarlink

Omalizumab is a humanized monoclonal IgG1 antibody approved by the US FDA for the treatment of chronic spontaneous urticaria (CSU) unresponsive to H1 antihistamines. Apart from CSU, the efficacy of omalizumab has been demonstrated in atopic dermatitis (AD), bullous pemphigoid (BP), hyper-IgE syndrome (HIES), mastocytosis and Kimura’s disease (KD), with the level of evidence varying for each disorder. Besides, in anecdotal reports, the benefits of omalizumab in TEN and Netherton syndrome have been highlighted.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Omalizumab

  • 章节

  • 发表日期：

    2025年

查看全文
  • Aditya Kumar Bubna

摘要

Omalizumab is a humanized monoclonal IgG1 antibody approved by the US FDA for the treatment of chronic spontaneous urticaria (CSU) unresponsive to H1 antihistamines. Apart from CSU, the efficacy of omalizumab has been demonstrated in atopic dermatitis (AD), bullous pemphigoid (BP), hyper-IgE syndrome (HIES), mastocytosis and Kimura’s disease (KD), with the level of evidence varying for each disorder. Besides, in anecdotal reports, the benefits of omalizumab in TEN and Netherton syndrome have been highlighted.